^
    Back
    Association details:
    Biomarker:SEMA7A overexpression
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:fulvestrant (Selective estrogen receptor degrader)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ENDO 2021
    Title:

    P54-42 - Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer

    Published date:
    01/21/2021
    Excerpt:
    ...in ER+ cell lines, overexpression of SEMA7A promotes in vitro growth in the face of estrogen-deprivation, tamoxifen, or fulvestrant treatments.